Medicare Coverage for PanTracer LBx Liquid Biopsy Shifts NeoGenomics' Diagnostic Narrative

NeoGenomics' PanTracer LBx liquid biopsy test has received Medicare coverage, widening access to a 500-gene test with a seven-day turnaround. This highlights the growing role of liquid biopsy in real-world cancer care for therapy selection and clinical trial matching. Medicare coverage addresses reimbursement concerns but does not resolve broader concerns about profitability and volatility in nonclinical revenue.